Merck’s (NYSE: MRK) Q4 and full-year 2023 results reflect sustained growth across oncology and vaccines. Our company announced Q4 worldwide sales of $14.6 billion, an increase of 6% from Q4 2022. Full-year 2023 worldwide sales were $60.1 billion, an increase of 1% from full-year 2022....
Gardasil China now is about 1% of our total earnings. So it is becoming -- of our total revenue. So obviously, that's an important thing to understand. And that's why we also highlighted that if you look at the way the business is going to progress, as we get into the back half ...
Oct 29, 2024 4:32 PM EDT Stock Market Today: Stocks blow past Treasury yield leap; Google on deck Another leg higher in Treasury bond yields is muting stock gains heading into a busy earnings session on Wall Street. ^IN Stock Investing News, Analysis and Tips Oct 1, 2024 3:51 AM ED...
Thank you, Caroline. Today, I will provide notable updates since our last earnings call. We continue to make significant advancements and achieve important regulatory milestones. The fourth quarter marks the end of a successful year with progress made across oncology, vaccines, infectious diseases and...
Will These 5 Big Drug Stocks Surpass Q4 Earnings Forecast The fourth-quarter earnings season for the drug and biotech sector will be in full swing this week with many large drugmakers like —Merck,Pfizer,Eli Lilly and Co.,AmgenandBristol Myers Squibb— due to announce results. Johns...
Good morning. My name is Lara and I will be your conference operator today. At this time, I would like to welcome everyone to the Merck & Co. Q4 Sales and Earnings Conference Call. [Operator Instructions] After the speaker’s remarks, there will be a question-and-answer session. [Operat...